Astrazeneca (AZN) Intangibles (2009 - 2026)

Astrazeneca (AZN) has reported Intangibles for 18 consecutive years, with $36.9 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Intangibles fell 1.71% year-over-year to $36.9 billion; the TTM figure through Mar 2026 stood at $36.9 billion (down 1.71% YoY), while the FY2025 annual figure was $37.8 billion, up 1.8% from the prior year.
• Intangibles came in at $36.9 billion for Q1 2026 at Astrazeneca, down from $37.8 billion in the prior quarter.
• The five-year high for Intangibles was $41.3 billion in Q1 2022, with the low at $2.7 billion in Q4 2023.
• Average Intangibles over 5 years is $36.5 billion, with a median of $38.3 billion recorded in 2023.
• Across the five-year window, Intangibles plunged 93.11% in 2023 and jumped 1273.37% in 2024, its largest moves.
• Year by year, Intangibles stood at $39.3 billion in 2022, then slumped by 93.11% to $2.7 billion in 2023, then surged by 1273.37% to $37.2 billion in 2024, then gained by 1.8% to $37.8 billion in 2025, then retreated by 2.48% to $36.9 billion in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $36.9 billion, $37.8 billion, and $38.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.